National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tofacitinib (Xeljanz®) in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.

Rapid Review

Commenced Completed Outcome
08/03/2017 28/04/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price